Other
Increase (Decrease) in Prepaid Expense and Other Assets
Alnylam Pharmaceuticals Increase (Decrease) in Prepaid Expense and Other Assets decreased by 91.1% to $6.32M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 80.7%, from $32.77M to $6.32M.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Large increases may indicate significant upfront payments for software licenses, insurance, or other long-term service contracts.
Detailed definition
The change in payments made in advance for goods or services to be received in future periods. This represents a use of...
Peer comparison
Standard working capital component found in the cash flow statement of most companies.
Metric ID:
other_increase_decrease_in_prepaid_deferred_expense_and__8bfef6Historical Data
17 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.97M | $18.14M | $29.85M | $21.31M | -$3.97M | $1.24M | $27.87M | $3.32M | $75.46M | -$61.69M | $8.28M | -$25.28M | $32.77M | -$6.78M | $20.74M | $70.99M | $6.32M |
| QoQ Change | — | +6.9% | +64.5% | -28.6% | -118.6% | +131.1% | >999% | -88.1% | >999% | -181.7% | +113.4% | -405.4% | +229.6% | -120.7% | +406.1% | +242.3% | -91.1% |
| YoY Change | — | — | — | +25.6% | -121.9% | -95.9% | +30.8% | +183.7% | >999% | -321.3% | +149.5% | — | -56.6% | +89.0% | +150.6% | +380.8% | -80.7% |
Range-$61.69M – $75.46M
CAGR-21.9%
Avg YoY Growth+488.0%
Median YoY Growth+30.8%
Increase (Decrease) in Prepaid Expense and Other Assets at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's increase (decrease) in prepaid expense and other assets?
- Alnylam Pharmaceuticals (ALNY) reported increase (decrease) in prepaid expense and other assets of $6.32M in Q1 2026.
- How has Alnylam Pharmaceuticals's increase (decrease) in prepaid expense and other assets changed year-over-year?
- Alnylam Pharmaceuticals's increase (decrease) in prepaid expense and other assets decreased by 80.7% year-over-year, from $32.77M to $6.32M.
- What does increase (decrease) in prepaid expense and other assets mean?
- The change in cash paid upfront for future expenses.